Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Currys lifts FY guidance again as sales, cash flow surge

(Sharecast News) - Electrical retailer Currys raised its annual profit outlook again with "significant" free cash flow underpinning the board's plan to resume dividend payments after a 4% rise in like-for-like sales since January. Currys said it expected full year adjusted pre-tax profit to be around £162m, a rise of 37% and up from estimates of £160m. It finished the period with net cash of more than £180m after rising sales and improving profit margins more than offset cost increases in the UK and Ireland.

In January, Currys said it would declare a dividend of around 1.3p a share with full-year results in July - its first since an interim payout in 2022/23.

The increase in sales was driven by its UK and Ireland division and a rebound in the Nordics business. Currys raised its profit forecast in April to around £160m on the back of strong trading since early January after also lifting estimates in the new year.

UK & Ireland adjusted operating profit was expected to be in line with consensus estimates of £152m according to a company compiled poll, with like-for-like sales increasing 4% the new year.

In the Nordics, operating earnings were in-line with expectations of £77m on a currency neutral basis, although reported profits had been impacted by currency headwinds. Growth accelerated in the final period of the year "despite a still challenging consumer environment", the company added.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.